Journal of Clinical Oncology, Vol 10, 606-613, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study

R Trueworthy, J Shuster, T Look, W Crist, M Borowitz, A Carroll, L Frankel, M Harris, H Wagner and M Haggard
Department of Pediatrics, University of Kansas, Kansas City.

PURPOSE: Using the technique of recursive partitioning and amalgamation analysis with verification, the Pediatric Oncology Group (POG) investigated the independent prognostic significance of previously published prognostic factors significantly associated with event-free survival (EFS) in B-progenitor cell acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: Age, leukocyte count, sex, immunophenotype (expression of cytoplasmic immunoglobulin [Ig] and of surface antigens CD10 and CD34), and DNA index (ratio of the flow cytometry-determined DNA content of leukemia cells to that of normal diploid cells) were the variables used in the evaluation of four antimetabolite-based chemotherapy regimens in 1,535 children with the newly diagnosed B- progenitor cell ALL between February 1986 and May 1990. RESULTS: There were three subgroups at widely different risks of treatment failure. A DNA index greater than 1.16 was the most prognostic feature. The final prognostic subgrouping was as follows: (1) DNA index greater than 1.16; (2) DNA index less than or equal to 1.16, age less than 11.0 years, and leukocyte count less than 50 x 10(9)/L; and (3) DNA index less than or equal to 1.16, (age greater than 11.0 years, and/or leukocyte count greater than 50 x 10(9)/L). These groups made up 20%, 53%, and 27% of the patients and had 4-year EFS rates (SE) of 90.1% (6.3%), 80.5% (5.1%), and 50.4% (7.6%), respectively. CONCLUSIONS: Use of the DNA index, leukocyte count, and age--data that are relatively inexpensive and simple to obtain--may be sufficient to stratify patients with B- progenitor cell ALL for risk-directed therapy. Patients at an extremely low risk of failing therapy (approximately 20% of cases in this study) can thus be identified and spared the toxic short-term and late effects of more intensive therapies that may be needed for children with less favorable clinical and biologic features.

This article has been cited by other articles:

				F. Tucci and M. Arico Treatment of pediatric acute lymphoblastic leukemia Haematologica, August 1, 2008; 93(8): 1124 - 1128. [Full Text] [PDF]

				V. Pullarkat, M. L. Slovak, K. J. Kopecky, S. J. Forman, and F. R. Appelbaum Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study Blood, March 1, 2008; 111(5): 2563 - 2572. [Abstract] [Full Text] [PDF]

				M. Arico, M. G. Valsecchi, C. Rizzari, E. Barisone, A. Biondi, F. Casale, F. Locatelli, L. Lo Nigro, M. Luciani, C. Messina, et al. Long-Term Results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: Insight on the Prognostic Value of DNA Index in the Framework of Berlin-Frankfurt-Muenster Based Chemotherapy J. Clin. Oncol., January 10, 2008; 26(2): 283 - 289. [Abstract] [Full Text] [PDF]

				K. R. Schultz, D. J. Pullen, H. N. Sather, J. J. Shuster, M. Devidas, M. J. Borowitz, A. J. Carroll, N. A. Heerema, J. E. Rubnitz, M. L. Loh, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG) Blood, February 1, 2007; 109(3): 926 - 935. [Abstract] [Full Text] [PDF]

				A. Moghrabi, D. E. Levy, B. Asselin, R. Barr, L. Clavell, C. Hurwitz, Y. Samson, M. Schorin, V. K. Dalton, S. E. Lipshultz, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia Blood, February 1, 2007; 109(3): 896 - 904. [Abstract] [Full Text] [PDF]

				C. Flotho, E. Coustan-Smith, D. Pei, S. Iwamoto, G. Song, C. Cheng, C.-H. Pui, J. R. Downing, and D. Campana Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2 Blood, August 1, 2006; 108(3): 1050 - 1057. [Abstract] [Full Text] [PDF]

				S. J. Laughton, L. J. Ashton, E. Kwan, M. D. Norris, M. Haber, and G. M. Marshall Early Responses to Chemotherapy of Normal and Malignant Hematologic Cells Are Prognostic in Children With Acute Lymphoblastic Leukemia J. Clin. Oncol., April 1, 2005; 23(10): 2264 - 2271. [Abstract] [Full Text] [PDF]

				C. Charrin, X. Thomas, M. Ffrench, Q.-H. Le, J. Andrieux, M.-J. Mozziconacci, J.-L. Lai, C. Bilhou-Nabera, L. Michaux, A. Bernheim, et al. A report from the LALA-94 and LALA-SA groups on hypodiploidy with 30 to 39 chromosomes and near-triploidy: 2 possible expressions of a sole entity conferring poor prognosis in adult acute lymphoblastic leukemia (ALL) Blood, October 15, 2004; 104(8): 2444 - 2451. [Abstract] [Full Text] [PDF]

				W. L. Carroll, D. Bhojwani, D.-J. Min, E. Raetz, M. Relling, S. Davies, J. R. Downing, C. L. Willman, and J. C. Reed Pediatric Acute Lymphoblastic Leukemia Hematology, January 1, 2003; 2003(1): 102 - 131. [Abstract] [Full Text] [PDF]

				P. J. Moos, E. A. Raetz, M. A. Carlson, A. Szabo, F. E. Smith, C. Willman, Q. Wei, S. P. Hunger, and W. L. Carroll Identification of Gene Expression Profiles That Segregate Patients with Childhood Leukemia Clin. Cancer Res., October 1, 2002; 8(10): 3118 - 3130. [Abstract] [Full Text] [PDF]

				J. T. Sandlund, P. L. Harrison, G. Rivera, F. G. Behm, D. Head, J. Boyett, J. E. Rubnitz, A. Gajjar, S. Raimondi, R. Ribeiro, et al. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia Blood, June 17, 2002; 100(1): 43 - 47. [Abstract] [Full Text] [PDF]

				A. M. Ford, K. Fasching, E. R. Panzer-Grumayer, M. Koenig, O. A. Haas, and M. F. Greaves Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes Blood, August 1, 2001; 98(3): 558 - 564. [Abstract] [Full Text] [PDF]

				A. T. Maia, A. M. Ford, G. R. Jalali, C. J. Harrison, G. M. Taylor, O. B. Eden, and M. F. Greaves Molecular tracking of leukemogenesis in a triplet pregnancy Blood, July 15, 2001; 98(2): 478 - 482. [Abstract] [Full Text] [PDF]

				D. L. Robinson Childhood Leukemia: Understanding the Significance of Chromosomal Abnormalities Journal of Pediatric Oncology Nursing, May 1, 2001; 18(3): 111 - 123. [Abstract] [PDF]

				E. Coustan-Smith, J. Sancho, M. L. Hancock, J. M. Boyett, F. G. Behm, S. C. Raimondi, J. T. Sandlund, G. K. Rivera, J. E. Rubnitz, R. C. Ribeiro, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia Blood, October 15, 2000; 96(8): 2691 - 2696. [Abstract] [Full Text] [PDF]

				A. M. Friedmann and H. J. Weinstein The Role of Prognostic Features in the Treatment of Childhood Acute Lymphoblastic Leukemia Oncologist, August 1, 2000; 5(4): 321 - 328. [Abstract] [Full Text]

				N. A. Heerema, H. N. Sather, M. G. Sensel, T. Zhang, R. J. Hutchinson, J. B. Nachman, B. J. Lange, P. G. Steinherz, B. C. Bostrom, G. H. Reaman, et al. Prognostic Impact of Trisomies of Chromosomes 10, 17, and 5 Among Children With Acute Lymphoblastic Leukemia and High Hyperdiploidy (> 50 Chromosomes) J. Clin. Oncol., May 9, 2000; 18(9): 1876 - 1887. [Abstract] [Full Text] [PDF]

				D. H. Mahoney Jr, J. J. Shuster, R. Nitschke, S. Lauer, C. P. Steuber, and B. Camitta Intensification With Intermediate-Dose Intravenous Methotrexate Is Effective Therapy for Children With Lower-Risk B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study J. Clin. Oncol., March 13, 2000; 18(6): 1285 - 1294. [Abstract] [Full Text] [PDF]

				N. A. Heerema, J. B. Nachman, H. N. Sather, M. G. Sensel, M. K. Lee, R. Hutchinson, B. J. Lange, P. G. Steinherz, B. Bostrom, P. S. Gaynon, et al. Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group Blood, December 15, 1999; 94(12): 4036 - 4045. [Abstract] [Full Text] [PDF]

				C. Ito, M.-a. Kumagai, A. Manabe, E. Coustan-Smith, S. C. Raimondi, F. G. Behm, K. G. Murti, J. E. Rubnitz, C.-H. Pui, and D. Campana Hyperdiploid Acute Lymphoblastic Leukemia With 51 to 65 Chromosomes: A Distinct Biological Entity With a Marked Propensity to Undergo Apoptosis Blood, January 1, 1999; 93(1): 315 - 320. [Abstract] [Full Text] [PDF]

				J. E. Rubnitz and C.-H. Pui Childhood Acute Lymphoblastic Leukemia Oncologist, December 1, 1997; 2(6): 374 - 380. [Abstract] [Full Text] [PDF]

				C. D. Jennings and K. A. Foon Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy Blood, October 15, 1997; 90(8): 2863 - 2892. [Full Text] [PDF]

				A. Borkhardt, G. Cazzaniga, S. Viehmann, M. G. Valsecchi, W. D. Ludwig, L. Burci, S. Mangioni, M. Schrappe, H. Riehm, F. Lampert, et al. Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials Blood, July 15, 1997; 90(2): 571 - 577. [Abstract] [Full Text] [PDF]

				J. E. Rubnitz and W. M. Crist Molecular Genetics of Childhood Cancer: Implications for Pathogenesis, Diagnosis, and Treatment Pediatrics, July 1, 1997; 100(1): 101 - 108. [Full Text] [PDF]

				M. J. Borowitz, J. Shuster, A. J. Carroll, M. Nash, A. T. Look, B. Camitta, D. Mahoney, S. J. Lauer, and D. J. Pullen Prognostic Significance of Fluorescence Intensity of Surface Marker Expression in Childhood B-Precursor Acute Lymphoblastic Leukemia. A Pediatric Oncology Group Study Blood, June 1, 1997; 89(11): 3960 - 3966. [Abstract] [Full Text] [PDF]

				C.M. Niemeyer, M. Arico, G. Basso, A. Biondi, A. C. Rajnoldi, U. Creutzig, O. Haas, J. Harbott, H. Hasle, G. Kerndrup, et al. Chronic Myelomonocytic Leukemia in Childhood: A Retrospective Analysis of 110 Cases Blood, May 15, 1997; 89(10): 3534 - 3543. [Abstract] [Full Text] [PDF]

				J. E. Rubnitz, J. J. Shuster, V. J. Land, M. P. Link, D. J. Pullen, B. M. Camitta, C.-H. Pui, J. R. Downing, and F. G. Behm Case-Control Study Suggests a Favorable Impact of TEL Rearrangement in Patients With B-Lineage Acute Lymphoblastic Leukemia Treated With Antimetabolite-Based Therapy: A Pediatric Oncology Group Study Blood, February 15, 1997; 89(4): 1143 - 1146. [Abstract] [Full Text] [PDF]

				C.-H. Pui Childhood Leukemias N. Engl. J. Med., June 15, 1995; 332(24): 1618 - 1630. [Full Text] [PDF]

				G. K. Rivera, D. Pinkel, J. V. Simone, M. L. Hancock, and W. M. Crist Treatment of Acute Lymphoblastic Leukemia -- 30 Years' Experience at St. Jude Children's Research Hospital N. Engl. J. Med., October 28, 1993; 329(18): 1289 - 1295. [Abstract] [Full Text]

				Media Review: References of Interest for the Pediatric Oncology Nurse Journal of Pediatric Oncology Nursing, January 1, 1992; 9(4): 196 - 198. [PDF]